6 results about "Rituximab" patented technology

The invention discloses an antigen expression vector, a combination of the antigen expression vector and an antibody and application of the combination in cancer treatment. The antigen expression vector comprises one or more DMP-antigen coding gene units; the DMP-antigen coding gene is composed of two functional elements DMP and an antigen coding gene, the DMP is an NF-kappa B specific promoter, and the antigen coding gene is an antigen molecule coding sequence. The antigen expression vector prepared by the invention can selectively express antigen molecules in cancer cells, an in-vivo delivery vector taking adeno-associated virus as the antigen expression vector, and a combination of an antigen CD20 expressed by the antigen expression vector and an anti-CD20 antibody rituximab. The compound has a good treatment effect on mouse colon cancer on mice and human colon cancer on humanized mice, and has good tumor targeting property and safety in the treatment of the cancer mice. The invention is expected to provide a new technology and a new reagent for the treatment of various cancer diseases.

This disclosure includes methods for treating cancer in a subject, the method comprising administering an anti-CD20 antibody and an immune cell expressing a therapeutic polypeptide (e.g., a TEAM) to the subject.

This document relates to methods and materials involved in identifying and / or treating mammals having membranous nephropathy (e.g., membranous nephropathy with an elevated level of a Semaphorin 3B polypeptide in the glomerular basement membrane (GBM)). For example, methods and materials for administering one or more immunosuppressive agents (e.g., corticosteroids, cyclosporine, or a B-cell reduction or depletion agent such as Rituximab) to treat a mammal (e.g., a human) having membranous nephropathy are provided.

Provided is use of NK cells in treating vitiligo and psoriasis. Specifically, provided are use of NK cells and a cancer-targeted drug in the preparation of a drug for treating patients with primary liver cancer or hepatocellular carcinoma accompanied by psoriasis, and use of NK cells and rituximab in the preparation of a drug for treating patients with hepatic cyst accompanied by psoriasis.

The invention discloses a targeted immunomodulatory fusion protein for treating systemic lupus erythematosus, an engineered stem cell preparation for expressing the fusion protein as well as a preparation method and application of the engineered stem cell preparation. The fusion protein is composed of an anti-human CD20 single-chain antibody, an enhanced human IL-10 variant and a flexible connecting peptide, the complete amino acid sequence is SEQ ID NO5, the affinity to CD20 is basically equivalent to or better than that of rituximab, and the IL-10 activity is 1.8 times that of a wild type. The engineered stem cell preparation is obtained by transfecting human umbilical cord mesenchymal stem cells through lentivirus and screening puromycin, and the preparation can stably secrete fusion protein and is specifically combined with CD20 positive B cells. In-vitro experiments prove that B cell proliferation and IgG secretion can be remarkably inhibited, the urine protein positive rate and the dsDNA IgG level can be reduced in an in-vivo MRL / lpr mouse model, kidney pathological injuries are relieved, and the survival rate is increased. Precise treatment is achieved through a synergistic mechanism of targeted enrichment and local high-activity IL-10 delivery, the side effect of systemic immunosuppression is avoided, and the clinical transformation value is high.